• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors

    12/12/23 7:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CLDI alert in real time by email

    Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the appointment of David LaPré to the company's Board of Directors effective January 1, 2024. The company also announced the resignation of Director Alfonso Zulueta effective November 29, 2023 and the resignation of Director Tom Vecchiolla effective January 1, 2024.

    "David LaPré brings a wealth of pharmaceutical industry experience, expertise in solving problems unique to this industry, and a solid understanding of the factors that drive shareholder value. His past experiences will help Calidi move forward as a company, advancing our portfolio of cancer immunotherapies into later stage clinical trials," said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. "We also thank Alfonso Zulueta for his service to Calidi Biotherapeutics and his counsel and advice, which have helped guide us to this point as a public company."

    David LaPré currently heads DGL Advisors where he works with leaders in the biopharma industry on technical operations strategy and execution. Previously, for over 20 years, he held senior executive roles in technical operations and supply chain management both in the United States and Switzerland at Roche/Genentech. In these roles, his responsibilities encompassed the commercialization, commercial manufacturing, and global distribution of new medicines. Mr. LaPré has a B.S. in Engineering and Life Sciences from Worcester Polytechnic Institute and a M.B.A. from New York University.

    "Calidi Biotherapeutics has assembled a world-class team of leaders and advisors with the expertise and skills needed to deliver effective allogeneic stem cell therapies to patient populations with few effective treatment options," said David LaPré. "I look forward to guiding Calidi's team and helping them improve operational excellence as they mature their organization."

    About Calidi Biotherapeutics:

    Calidi Biotherapeutics (NYSE:CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer with a novel stem cell-based therapy delivering a payload to target and kill tumor cells. Calidi Biotherapeutics is advancing potent allogeneic stem cell-based platforms capable of carrying anti-tumor payloads for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.

    Forward-Looking Statements

    This press release may contain forward-looking statements for purposes of the "safe harbor" provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as "anticipates," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predicts," "project," "should," "towards," "would" as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. Any forward-looking statements contained in this discussion are based on Calidi's current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Calidi will be those that it has anticipated. Any forward-looking statements involve a number of risks, uncertainties (some of which are beyond Calidi's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Other risks and uncertainties are set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Company's Registration Statements filed with the SEC on Form S-4 filed on August 2, 2023, on Form S-1 filed on October 6, 2023 and Form 10-Q filed on November 14, 2023.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231212249768/en/

    Get the next $CLDI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CLDI

    DatePrice TargetRatingAnalyst
    11/22/2023$11.00Buy
    H.C. Wainwright
    10/9/2023$9.00Outperform
    Robert W. Baird
    More analyst ratings

    $CLDI
    SEC Filings

    See more
    • SEC Form S-1 filed by Calidi Biotherapeutics Inc.

      S-1 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

      7/3/25 5:27:03 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Calidi Biotherapeutics Inc.

      DEFA14A - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

      5/23/25 4:01:32 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Calidi Biotherapeutics Inc.

      DEF 14A - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

      5/23/25 4:00:12 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CLDI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Calidi Biotherapeutics Announces Shareholder Letter from CEO

      SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads, issued the following shareholder letter from its Chief Executive Officer, Eric Poma, PhD. Dear Shareholders, 2025 has been and will continue to be a transformative year for Calidi. We have made substantial changes in the company's leadership, its focus and priorities, and in its balance sheet and operating expenses. I am thrilled to have joined as Chief Executive Officer in April 2025. I am honored to lead this incredible organization

      6/27/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting

      SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads, today announced the presentation of its lead RedTail platform candidate, CLD-401, at the American Society of Clinical Oncology (ASCO) Annual Meeting. Calidi has previously demonstrated its pioneering efforts in developing an enveloped form of its proprietary oncolytic virus that is significantly more resistant to immune clearance than non-enveloped forms, allowing for systemic delivery and efficacy in syngeneic tumor-bearing pre-clinical

      6/2/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

      Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

      5/14/25 4:30:00 PM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CLDI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Poma Eric E

      4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      4/25/25 6:05:05 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Poma Eric E

      3 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      4/25/25 6:01:32 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Stewart Alan R. was granted 12,771 shares, increasing direct ownership by 79% to 28,976 units (SEC Form 4)

      4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      1/3/25 5:27:37 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CLDI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Calidi Biotherapeutics with a new price target

      H.C. Wainwright initiated coverage of Calidi Biotherapeutics with a rating of Buy and set a new price target of $11.00

      11/22/23 7:15:52 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Calidi Biotherapeutics with a new price target

      Robert W. Baird initiated coverage of Calidi Biotherapeutics with a rating of Outperform and set a new price target of $9.00

      10/9/23 7:23:07 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CLDI
    Financials

    Live finance-specific insights

    See more
    • Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

      Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platform Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial to treat multiple solid tumorsCommencement of recruitment for Phase 1 trial in patients with newly diagnosed high-grade glioma at Northwestern University hospital14 patients enrolled in Phase 1 trial conducted by City of Hope to treat recurrent high-grade glioma SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and fu

      3/31/25 4:10:00 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessCalidi: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Mark White, CEO of Nexalin Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate

      10/25/24 9:00:00 AM ET
      $CLDI
      $NXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 18, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE:CLDI) and Gorilla Technology Group Inc. (NASDAQ:GRRR) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 19, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Calidi: https://www.redchip.com/assets/access/cldi_accessGorilla Technology: https://www.redchip.com/assets/access/grrr_accessIn an exclusive interview, Stephen Thesing, Chief Business Officer of Calidi, appears on the RedChip Small Stocks Big Money™ show on Bloombe

      10/18/24 8:45:00 AM ET
      $BOXL
      $CLDI
      $GRRR
      Other Consumer Services
      Real Estate
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CLDI
    Leadership Updates

    Live Leadership Updates

    See more
    • Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

      Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

      5/14/25 4:30:00 PM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

      SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that in connection with the appointment of Eric Poma, Ph.D. as Chief Executive Officer , the Company's Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Dr. Poma for the purchase of 726,412 shares with an exercise price of $0.469, which was the closing price of the Company's common stock on April 22, 2025, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stoc

      4/25/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

      4/23/25 8:00:00 AM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CLDI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Calidi Biotherapeutics Inc.

      SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

      11/14/24 2:05:25 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Calidi Biotherapeutics Inc.

      SC 13G - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

      9/11/24 4:04:09 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care